Featured Research

from universities, journals, and other organizations

Antibody fragment effectively fights Alzheimer's disease in mice

Date:
October 25, 2013
Source:
Universitat Autňnoma de Barcelona
Summary:
Researchers have conducted trials with mice by injecting a specific antibody fragment against soluble aggregates of the Ab peptide, responsible for the toxicity and cell death characteristic of Alzheimer's disease. The beneficial effects were seen at the behavioural, cellular and molecular levels five days after an intraperitoneal dose was administered.

Researchers at the Biosciences Unit of the Department of Biochemistry and Molecular Biology at the Universitat Autňnoma de Barcelona (UAB), in collaboration with the UAB Institute of Neurosciences (INc), have conducted trials with mice by injecting a specific antibody fragment against soluble aggregates of the Ab peptide, responsible for the toxicity and cell death characteristic of Alzheimer's disease. The beneficial effects were seen at the behavioural, cellular and molecular levels five days after an intraperitoneal dose was administered.

Related Articles


Since the first case of Alzheimer's disease was described, the disease has been associated with the presence of insoluble deposits known as amyloid plaques. However, in the past decade researchers have been able to conclude that the neuronal death characteristic of the disease is not due to the presence of these plaques but rather to the toxicity of the soluble aggregates preceding them (and called oligomers), formed by the Ab peptide.

Immunotherapy, consisting of the use of antibodies as a treatment for disease, is turning out to be an encouraging tool for the treatment of certain types of cancer and has also been used in clinical trials to treat Alzheimer's disease. Nevertheless, the clinical trial which had advanced the most in treating Alzheimer's through passive vaccination -- using the bapineuzumab antibody -- was halted in 2012 during its last trial phase due to controversial adverse effects and benefits of the treatment. Many scientists think the effects were the result of administering complete antibodies, which produce inflammation in the brain. For this reason, they propose that administering antibody fragments instead would be much safer.

The research group directed by Dr Sandra Villegas, from the Biosciences Unit of the Department of Biochemistry and Molecular Biology at the UAB, designed a recombinant antibody fragment (the single-chain variable fragment scFv-h3D6), a derivative of bapineuzumab, which only consists of the active part trapping the etiological agent of the disease: the domains of the antibody responsible for the binding of Aβ oligomers. Scientists observed how this antibody fragment protected from cell death in human cell-cultures and described the molecular mechanism by which this antibody fragment removed the Aβ oligomers that cause the disease.

In the latest edition of mAbs (monoclonal antibodies), a journal specialized in immunotherapy, the research group has published three articles which demonstrate the benefits of the treatment using the antibody fragment scFv-h3D6 in mice, and have redesigned the molecule to make it even more efficient.

The mice come from the 3xTg-AD colony, an animal model of Alzheimer's disease, provided by Dr Lydia Giménez-Llort of the UAB Institute of Neurosciences (INCs). Researchers observed how a single injection into the abdomen of the animals and five days later, the mice reversed their levels of anxiety to normal levels and the learning and memory deficits were ameliorated. At the molecular level, researchers demonstrated two important facts: first, the treatment cleared from the cerebral cortex the Ab peptide oligomers, the elements causing the disease; and second, this clearence is linked to the recovery of the levels of certain apolipoproteins suspected to be the natural removers of Aβ peptide aggregates. The study on these apolipoproteins was conducted in collaboration with Dr Jose L. Sánchez-Quesada, from the Research Institute of the Sant Pau Hospital.

The results of the studies at the cellular level were also very encouraging. In addition to demonstrating that in young mice with the disease neuronal death occurs even in the cerebellum, UAB scientists observed how the antibody fragment protected the neurons, either fully in the less involved areas or partially in the most involved ones.

With the goal of improving the molecule, especially in regard to how long it can remain in the blood stream, the UAB group redesigned the molecule based on a molecular model developed in collaboration with Dr Baldo Oliva from the UPF-IMIM. The mutations introduced increase the thermodynamic stability by 25% and decrease the tendency to aggregate to some 4şC, traits which clearly increase the therapeutic potential of the scFv-h3D6 fragment to treat Alzheimer's disease. Additionally, the published redesign can also be useful for other antibody fragments being produced in other laboratories with the aim of finding effective treatments for several diseases.


Story Source:

The above story is based on materials provided by Universitat Autňnoma de Barcelona. Note: Materials may be edited for content and length.


Journal References:

  1. Lydia Giménez-Llort, Geovanny Rivera-Hernández, Marta Marin-Argany, José L. Sánchez-Quesada and Sandra Villegas. Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease. mAbs, October 2013
  2. Gisela Esquerda-Canals, Joaquim Marti, Geovanny Rivera-Hernández, Lydia Giménez-Llort and Sandra Villegas. Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment. mAbs, October 2013
  3. Geovanny Rivera-Hernández, Marta Marin-Argany, Bernat Blasco-Moreno, Jaume Bonet, Baldo Oliva and Sandra Villegas. Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency. mAbs, October 2013

Cite This Page:

Universitat Autňnoma de Barcelona. "Antibody fragment effectively fights Alzheimer's disease in mice." ScienceDaily. ScienceDaily, 25 October 2013. <www.sciencedaily.com/releases/2013/10/131025091707.htm>.
Universitat Autňnoma de Barcelona. (2013, October 25). Antibody fragment effectively fights Alzheimer's disease in mice. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/10/131025091707.htm
Universitat Autňnoma de Barcelona. "Antibody fragment effectively fights Alzheimer's disease in mice." ScienceDaily. www.sciencedaily.com/releases/2013/10/131025091707.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins